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ABSTRACT
A group of Influenza viruses, RNA containing viruses of the
Orthomyxoviridae family, consists of Influenza virus types A-D
and has been known to cause the Flu, a respiratory illness
associated with numerous detrimental symptoms that can lead to
death. Influenza A virus (IAV) is constantly changing and is
capable of causing pandemics. Currently used diagnostic methods
include virus culturing, immunoassays including rapid influenza
detection tests (RIDTs), and molecular assays including those
based on RT-PCR. Most of the methods can be only performed in
the certified diagnostic laboratories equipped with
sophisticated instrumentation and/or special biosafety
facilities. The results using these methods are not available on
a timely basis. RIDTs provide response within 15 minutes but are
unable to differentiate between the IAV subtypes. New diagnostic
technique, which allows reliable detection of the influenza
virus infection and virus genotyping at point-of-care setting,
are needed to prevent the spread of the virus and the occurrence
of a pandemic. In this project, we propose to use split Gquadruplex (G4) peroxidase probes targeting a fragment of the
IAV genome amplified using an isothermal RNA amplification
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reaction for the detection of IAV infection and virus
genotyping. The probes selectively report the virus RNA target
with a color change, which can be read by the naked eye.
They are capable of differentiating the targets containing as
little as a single-nucleotide variation in their sequences. This
study aims to optimize the probes, test their selectivity, and
calculate the detection limit.
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INTRODUCTION
Influenza virus can cause the flu, an exceedingly contagious
illness that globally affects the respiratory system of humans
and/or animals. Four types of the influenza virus exist today:
Influenza A, B, C, and D [1]. The vast majority of the influenza
viruses cause acute forms of infection depending on sudden and
gradual inclines of the symptoms associated with the strain.
Symptoms range from fever, sore throat, body aches, headaches,
stiffy coughs and a runny nose [2]. Even though these symptoms
can be weakened, they can last up to weeks or months and may be
severe if they include a bacterial agent that can further
develop into infections and detrimental recurring health
conditions, such as diabetes or cardiovascular diseases.
According to the Centers for Disease Control and Prevention
(CDC), 12,000 to 79,000 people can potentially die from the flu
each year since 2010 and approximates 9.3 million and 49.0
million individuals being ill with the flu [3]. Thus, immediate
detection of the virus is crucial. The virus symptoms can be
confused with other infections, e.g. common cold [4]. Therefore,
symptomatic diagnosis is not very reliable. Current techniques,
such as Reverse Transcriptase Polymerase chain reaction (RTPCR), Rapid influenza Test Diagnostic (RITD),
immunofluorescence, viral cultures, and serological tests result
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in delays with diagnostics and treatment of potential pandemic
phenomenon because they require expensive lab- dependent
instrumentation and are limited in their sensitivity,
specificity, and potentiality to distinguish influenza types and
IAV subtypes [5,6].

Therefore, new techniques that are robust,

reliable and affordable, and can be used at the point-of-care
(POC) settings (e.g. clinics or doctor’s office) are required to
enable efficient Influenza virus diagnostics for timely
treatment and control.
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BACKGROUND
Influenza Virus Structure
Influenza virus is an enveloped, single-stranded, negative-sense
RNA virus belonging to the family of orthomyxoviruses. The viral
genome is comprised of seven or eight RNA segments, which are
associated with several proteins including a nucleocapsid
protein, matrix protein (M1 and M2) nonstructural proteins (NS1
and NS2) and three RNA polymerases (Polymerase basic 1: PB1,
PB2, and Polymerase Acidic: PA) (Figure 1) [7,8]. Influenza A
and B consisting of 8 ssRNA strands and Influenza C of 7 [8].
The virion is enclosed by a lipid membrane with a layer of
matrix protein (M1) attached to it from inside. Two different
proteins, hemagglutinin (HA) and neuraminidase (NA) spike the
outside of the viral particle. HA plays an essential role in
viral recognition, while the NA component provides the virus
with the ability to remove from the host cell to enable
infection of other cells [9]. To infect the host cell, the virus
interacts with the cell via binding of HA to sialylated
receptors on the cell surface followed by endocytosis, fusion
with endosomes, uncoating and the release of genomic RNA into
the cytoplasm of the infected cell (Figure 2). Transcription and
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replication of the viral genome occurs in the nucleus of the
host cell, and the proteins are synthesized in the cytoplasm to
be assembled into viral ribonucleoproteins (vRNPs) and then to
newly formed virus particles, which are released from the
infected cell to start another infection cycle.

Figure 1. A schematic diagram of the influenza A virus [10].
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Figure 2. Influenza virus life cycle [11].

Interaction of the HA virus component with cellular
receptors represents an important factor in influenza virus
infection mechanism. The HA protein recognizes sialic acid and
galactose chains of the receptors (Figure 2). Human influenza
virus binds to the glycans containing alpha (2,6) linkages,
while avian influenza (AI) bind to the receptors with alpha
(2,3)-linked sialic acid. This has shown to play a crucial role
in preventing AI viruses from infecting humans. Thus, a switch
5

from alpha (2,6) sia linkages to alpha (2,3) sia linkages, can
generate a pandemic [12]. Figure 3 demonstrates the change of
(2,6)–glycosidic bond, typically seen in humans, to a (2,3)
glycosidic linkage, when infected by Avian flu.

Figure 3. A representation of the binding site for influenza virus to
neuraminic acid (sialic acid) connected to galactose via a (2,6) to a (2,3)
linkage [13].
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Classification of the Influenza virus subtypes
Antigenic drift is a mechanism that causes the diversification
of a virus and is correlated with existing mutations that occur
within genes that code for antibody-binding site and causes
reinfection [14]. Classification of the coexisting variants of
the influenza virus are based on antigenic differences that
exist within the nucleoprotein and matrix protein [15]. The
history of IAV dates all the way back to the early 1900s till
today. The severity of the different strains of IAV play a huge
role on population health across the globe. Of the four types,
Influenza C primarily evokes moderate respiratory illnesses that
do not develop into an outbreak, and Influenza D affects cattle
and has not been found to affect humans [16]. On the contrary,
both influenza A and B viruses cause seasonal outbreaks in the
United States, however, IAV predominates all types and its
austere effects can and do lead to pandemics that affect
multiple mammalian species, while influenza B almost exclusively
affects humans [16]. IAV has been further classified into
subcategories due to its diversity. There are currently 18
variations in the HA protein and 11 in the NA protein, thus an
additional classification system based on the type on HA and NA
has been developed [17]. The categories for the HA subtypes are
classified phylogenetically; Group 1 contains H1, H2, H5, H6,
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H8, H9, H11-H13, H16, H17 and group 2 with H3, H4, H7, H10, H14,
and H15. One of the subtypes, H5N1, originated in China in 1997
and now includes 10 phenotypically diverged clades in different
areas geographically. While Group 1 for NA contains N1, N4,N5,
and N8, and group 2 contains N2, N3, N6, N7, and N9 [9].
Among influenza viruses, IAV is very diverse, with high
potential of causing pandemics. Phylogenetic studies exhibit a
connection between the emergence of IAV to aquatic birds. This
is referred to as Avian influenza (of type A) which means that
the virus was acquired in birds and resulted in infection [19].
However, wild aquatic birds do not typically show signs of the
diseased state of the influenza virus and are considered to have
acquired adaptation to the virus itself [20]. While, domestic
bird species (ducks, turkeys, and chicken) can become highly
infected with the virus and sometimes result in death [19].
According to the World Health Organization, the H5N1 subtype of
AIV, transmitted from birds to humans, shows an increase in
clinical cases in 2003 and a 54% mortality rate from 2010-2014
[21]. According to CDC, the influenza activity during the year
of 2017-2018 was attributed to the A(H3N2) strain which had
showed a 10 % increase in mortality during the months of
December through April [22]. Thus, more attention is placed on
monitoring and detecting IAV.
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Treatments and preventions of IAV

It is crucial to diagnose illness the virus in its pre-developed
form. Meaning, if the virus is debilitated at an early stage, it
can prevent the spreading of the virus and entail morbidity.
Immunocompromised hosts that get in contact with the influenza
virus, under weak immune conditions, can cause these antigenic
viral entities to replicate [23]. Prescribed medication, such as
antiviral drugs (oseltamivir, zanamivir, peramivir) are
currently used to reduce the severity of flu, i.e. pneumonia,
bodily infections, and death [24]. At the same time, they have
been known to cause clinical implications due to their
availability and efficacy. Studies have also found the influenza
virus to be gaining slow resistance to antiviral drugs such as
neuraminidase inhibitors (NAIs), M2 inhibitors, and a polymerase
inhibitor (favipiravir) [25,26,27]. There are currently four
NAIs, oseltamivir, zanamivir, peramivir, and laninamivir that
show scattered drug resistance profiles due to both chemical and
structural variance. For instance, a mutated version of the
oseltamivir- resistant Influenza A(H1N10) strain in 2007-2008
emerged and spread to affect populations world-wide. In the case
of M2 inhibitors, amantadine and rimantadine develop rapid
resistance to IAV exclusively and are therefore limited in use
9

[26]. Due to the growth in anti-influenza drug-resistance [27]
and overall lack of efficient anti-influenza treatment options,
the main approach in fighting IV infection is its prevention by
vaccination. Once the host becomes infected with the flu,
vaccination is not as beneficial when it comes to reducing or
curing symptoms [28]. At the same time, high mutation rate
characteristic for IV and diverse range of viral subtypes that
can circulate and cause the infection make virus genotyping a
priority for the influenza infection surveillance.
Currently used methods for Influenza virus diagnostics
To ensure proper treatment, to limit IV transmission and prevent
epidemics and pandemics, early detection of the virus is
crucial. According to CDC, methods for influenza testing can be
classified into the ones based on viral culture, immunoassays
and nucleic acid amplification tests (NAATs) [29]. Various IAV
detecting methods and their suitability in distinguishing
between different virus strains and IAV subtypes are summarized
in Table 1.
Culture-based methods are important for virus genotyping to
enable proper viral strain surveillance and monitoring of new
stains appearance. At the same time, such methods can be only
performed in specialized diagnostic laboratories with BSL-2 or
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even BSL-3 certification, and they are lengthy, which makes them
non-applicable for routine patients’ diagnostics [29].
Immunoassays and NAATs are preferred diagnostic tools,
especially during suspected outbreaks of influenza infection.
Among immunoassays, rapid influenza diagnostic tests (RIDTs) are
commercially available and most commonly used. These tests can
identify the presence of nucleoprotein antigens from influenza A
and/or B viruses. They provide yes/no response within 15 minutes
with low to moderate sensitivity (true positive rate) and high
specificity (true negative rate). Due to insufficiently high
sensitivity of RIDTs responsible for high percentage of false
negative outcomes, negative results need to be confirmed by more
sensitive culture-based methods and/or NAATs based on RT-PCR.
RIDTs vary in their ability to detect and/or differentiate
between IAV and IBV, but neither of them is able to perform IAV
typing. Other immunoassay, for example, immunofluorescence
assays are sensitive, specific, and can distinguish between A
and B Influenza virus; however, they can take hours, are
technically complex, and require highly trained personnel to
obtain outcomes [29,30,].
In contrast to RIDTs, molecular diagnostics relying on RT-PCR
can provide information on a specific virus genotype with high
sensitivity and specificity. However, it requires sophisticated
instrumentation and personnel expertise for detection that can
11

be very time consuming. At the same time, there are two FDAcleared rapid molecular assays available for use in the USA.
These tests provide results in 15-20 min.

Other methods of IV

detection are mostly used in virologic research in the lab and
include gel electrophoresis using Southern Blots [31], Northern
blots [32], and cytological approaches utilizing fluorescence.
While there are some benefits to using these methods, such as
detection at lower levels, high sensitivity, specificity, etc.
these techniques vary depending on the individual qualification
when handling the instruments and samples and other limiting
factors (i.e. time-consuming, availability, cost intensive,
instrument dependent, temperature-dependent).
Table 1: Currently available influenza virus detection techniques [30].
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METHODOLOGY
Hypothesis
The focus of this study was on the development of a point-ofcare compatible diagnostic assay for IAV detection and
genotyping. IAV was selected among other influenza virus types
due to its diversity and potentiality in causing pandemics. We
proposed to use binary G4 peroxidase probes to interrogate a
fragment of IAV genome with high selectivity necessary for IAV
genotyping and generation of a color change as a visually
readable signal without instrumentation needed. We hypothesized
that it is possible to design split peroxidase probes to
differentiate between subtypes H1N1, H3N2 and H5N1 by tailoring
the probe sequence to a fragment of the viral segment 4
containing single-nucleotide differences between the genotype
genomes. We also believed that the signal can easily be read by
the naked eyes. Thus, we designed and optimized split G4
peroxidase probes for IAV detection and differentiation between
IAV H1N1, H3N2 and H5N1 genetic signatures.
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Colorimetric (visual) assay

Strands α and β (each at 1 µM) were mixed with the analyte
(0.05-1 µM) in a Col buffer containing (35 µL) of 2x conc. Col
and RNase-free water (34 µL). Another sample containing only the
probe, but not the analyte, served as the blank. Hemin (0.375-1
µM), freshly prepared ABTS solution in DMSO (1 mM) and freshly
prepared aqueous H2O2 (1 mM) were added to the samples and
incubated for different periods (15-60 min) at 22 °C followed by
measurement of the samples’ absorbance (λ of 420) using a
Nanodrop OneC instrument. The tube images were captured with a
smartphone camera.
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RESULTS
Design of split peroxidase probes
G-quadruplex (G4) peroxidase probes are comprised of two strands
of DNA –  and , each of which contains an analyte-binding arm
and a signal transducer-forming domain made of guanine (G)
triplets (Figure 4) [33]. The sequence of the signal transducer
domain is inspired by a peroxidase like DNA enzyme PW17 (Figure
4A) [33]. The two subunits of a split (binary) DNA peroxidase
(Figure 4B) are inactive unless a specific nucleic acid analyte
fully complementary to the analyte-binding arms of strands  and
 is present to form a catalytically active complex shown in
Figure 4C. The G4 domain of the complex binds hemin to catalyze
a peroxidation reaction that converts a colorless organic
substrate (e.g. 2,2′-Azino-bis (3-ethylbenzthiazoline-6-sulfonic
acid), ABTS) into its colored oxidation product [33,34]. This
signal can be conveniently detected with the naked eye or
quantified using a spectrophotometer. This type of signaling is
very beneficial since it can be easily read by most individuals.
To ensure high selectivity of the target recognition down
to single nucleotide differentiation, the probes were designed
so that one of the analyte-binding arms was relatively short (9
nt with Tm of 24 °C) and thus could efficiently bind only the

15

fully matched target fragment at room temperature. At the same
time, to ensure high affinity of the two-component probe to the
target, the analyte-binding arm of the second strand was 18 nt
(Tm of 55 °C) and bound to both the fully complementary and the
mismatched targets.

16

D)

E)

Figure 4. Design of a split (binary) G4 DNA peroxidase and its interaction
with a nucleic acid analyte.
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Figure 4. A) Sequence of a peroxidase-like DNA enzyme PW17 used
as a model for the binary DNA peroxidase design. B) PW17
sequence is split into two parts – α and β - to form a binary
DNA peroxidase. Each part is elongated with a fragment
complementary to a nucleic acid analyte of interest, which is
connected to a PW17 fragment with a triethylene glycol linker to
ensure flexibility of the construct when bound to the analyte.
C) Interaction of the binary peroxidase probe designed to target
rs242557 single-nucleotide polymorphism (SNP) site with its
complementary analyte. When the analyte is bound, the signal
transducing domain of the construct (G4 peroxidase) is formed to
catalyze a peroxidation reaction resulting in a green–colored
reaction product (D). The green color is due to peroxidation of
ABTS (E).
The G–triads participating in the G-quadruplex formation (Figure
4C) can be arranged in a 1:3, 3:1, or 2:2 pattern on the
unwinding and selective arms (Figure 5). Naming starts with the
unwinding arm (blue) followed by the selective arm (orange).
Thus, a 2:2 denotes 2 G–triads on the unwinding arm followed by
2 G–triads on the selective arm.
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Figure 5. Splitting Patterns.

In this study, we developed a diagnostic assay for immediate
detection of the influenza virus. First, we designed split G4
peroxidase probes (Table 2) to target segment 7 of IAV genome,
which encodes for the matrix (M) protein. Conserved mutations in
the matrix proteins are unique to each strain and is sufficient
for genotyping. The probes were tested and optimized using a
synthetic DNA analyte mimicking the interrogated fragments of
IAV genome of strain H1N1. We then detected the selectivity
using sequences (table 2) corresponding to the interrogated
fragments of the genomes of strains H3N2 and H5N1. To ensure
high selectivity of the sensors, the analyte binding arm, was
designed short enough to enable the formation of the
catalytically active complex only in the presence of the fully
matched analyte. In this study, we demonstrated that split G4
DNA peroxidase probes represent an effective advancement in
molecular diagnostics at an inexpensive platform for Influenza
virus analysis.
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Table 2: Probe design sequences used to selectively differentiate between H1N1,
H3N2, and H5N1. Color coding is used to show changes applied to the unwinding (U)
and selective (S) arm sequence; mutation sites are indicated in red.

Analytes

Probe 1

H1N1

GACTAAGGGAATTTTAGGATTTGTGTTCACGCTCACCGTGCCCAGTGAGCGAGGAC

H3N2

GACTAAGGGGATTTTAGGGTTTGTTTTCACGCTCACCGTGCCCAGTGAGCGAGGAC

H5N1

GACTAAAGGGATGTTGGGATTTGTATTCACGCTCACCGTGCCCAGTGAGCGAGGAC

H1N1 S

TTGGGTTGAACACAA

H3N2 S

TTGGGTTGAAAACAA

H5N1 S

TTGGGTTGAATACAA

U

ACTGGGCACGGTGAGCGTTGGGTTGGGTTGGGT

Probe 2

U2a

CCAACTGGGCACGGTGAGCGTTGGGTTGGGTTGGGT

Probe 3

U2b

ACCCAACTGGGCACGGTGAGCGTTGGGTTGGGTTGGGT

Probe 4

U3

ACTGGGCACGGTGAGCGTTGGGTT

H1N1 S2

TGGGTTGGGTTGGGTTGAACACAA

H3N2 S2

TGGGTTGGGTTGGGTTGAAAACAA

H5N1 S2

TGGGTTGGGTTGGGTTGAATACAA

Assay time
The color change triggered by the presence of a specific target
can be observed almost immediately after addition of ABTS and
hydrogen peroxide (Fig. 6).
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Optimization
Sensor designs and design optimization
To distinguish between the IAV strains, we first designed and
optimized an assay of split G4-peroxidase (sPDz) probes to
detect selectivity of the IAV and calculate the Limit of
Detections. Sensors are optimized to interrogate a Single
Nucleotide Polymorphism (SNP) of segment 7 of the IAV genome
using the analytes listed in Table 2. This is achieved by
optimizing the length of the α and β sensor arms to form a
binary DNA peroxidase. The panel of sPDz probe 1 exhibited the
same signal intensity for the samples in the absence of a target
(Fig. 7A, NTC), and in the presence of either analyte. High
background resulted from the peroxidase-like activity of the
unwinding U1 strand by itself (Fig. 7B), which could be
attributed to the formation of a monolith G4 structure (Fig.
7C), as predicted by Nupack software. To decrease the
background, the G4-forming sequence of the unwinding strand U1
was partially sequestered by a stem formation. Two new unwinding
strands – strands U2a and U2b – were designed. When used with
the original selective strand S, these strands formed probe 2
and probe 3, respectively (Table 2). Strand U2a contained a 3nucleotide “tail” at the 5’-end (Fig. 8), while strand U2b had a
5-nucleotide “tail” (Fig. 9). The “tail” addition to the
21

unwinding sPDz strand helped to slightly decrease the background
(down to A420~0.5 a.u.) but decreased the target-dependent
signal. Still, no selectivity was observed. Next, the splitting
of the G4-forming sequence of the probe was changed to make
probe 4, which contained 1 G-triplet on the unwinding strand
(strand U3), while the selective strand contained three Gtriples (strands S2). Thus, a 1:3 instead of 3:1 splitting
pattern of the G4 signal transducer was employed (Fig. 5). Probe
4 interrogated H1N1 IAV genotype with excellent selectivity
(Fig. 10A). The same approach was used to design the probes
targeting other genotypes of IAV – H3N2 and H5N1. Both probes
exhibited good selectivity (Fig 10, panels B and C,
respectively). To determine the effect of parameters of sensor
concentration on LoD, we evaluated strain H1N1 at different
concentrations (0.05, 0.1, 0.2, 0.5 1.0, and 2.0 Nm). The data
was plotted, and the regression line gave a slope– intercept
equation (Y = 1.1076x + 0.1218) that was based to calculate LOD,
resulting in 0.1383887. This is the lowest analyte concentration
reliably distinguishable from the blank. This value is
consistent with the calculations for sensors with similar
targets [35]. The R2 values was 0.9884.
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Figure 6. Time dependence for visual readout.
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Figure 7. Performance of probe 1. (A) Selectivity. (B) Signal generated by each strand of
the probe in the absence of a target. (C) Predicted secondary structure of U1 strand showing
proximity of the G4-forming fragments due to the stem formation. Predicted using Nupack
software (nupack.org).
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Selectivity of IAV subtype– specific sensors
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1.6
1.4
Absorbance, a.u.

1.2
1

0.8
0.6
0.4
0.2
0

NTC

H1N1

H3N2
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DISCUSSION
Genotyping of IAV is important for influenza infection
surveillance and pandemic prediction. Split G4-peroxidase (sPDz)
probes provide a quick alternative for the identification and
differentiation of IAV strains. There have been numerous reports
on the various techniques (i.e. RT-PCR, Serological tests, RITD,
etc.) used for the detection of the influenza A virus. However,
the clinical utility of these methods is not effective in
robustly distinguishing between pandemic IAV strains due to
their limitations in providing results in a timely manner and
their dependency on specialized laboratory instruments. Split
G4-peroxidase probes, when combined with an isothermal method
for the viral RNA amplification, have been established as a
promising technique for single nucleotide changes, providing an
innovative approach for point-of-care system. visually readable
signal without instrumentation needed. We have demonstrated that
the probes can detect a single nucleotide polymorphism through
our selection of a specific region that contained a single
nucleotide difference, within each target (Table 2). Here we
also report a methodology that utilizes sPDz sensors
interrogating segment 7 of the IAV genome for the detection of
strains H1N1, H3N2, H5N1. The assay requirements of substrate of
choice, ABTS and split sensors based on a G-quadruplex (G4)
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peroxidase-like deoxyribozyme offer a low cost, rapid diagnostic
platform. The benefits of sPDz sensors include high selectivity
of the viral target interrogation, tolerance to stable secondary
structure of the target, and easy visualization of the target
detectable by the naked eyes. Our results indicate that the
sensors have the ability to immediately detect the color change
triggered by the presence of a specific target, even after a
minute of mixing with ABTS and hydrogen peroxide.
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Future Research
Subsequent development of the sPDz probes will involve testing
on the optimized H1N1-targeting sPDz probe with IAV RNA
amplified using an isothermal amplification technique (e.g.
nucleic acid sequence–based amplification, NASBA). In our
follow-up study, we plan to validate our method using clinical
samples (serum, saliva, etc.) of patients infected with
influenza virus, and compare the performance of our method with
currently used PCR-based diagnostic tools.
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CONCLUSION
We have developed a panel of sPDz probes based on G4 peroxidaselike deoxyribozyme that display selectivity in accordance with
the sequences of strain H1N1, H3N2, and H5N1 of the IAV genome.
The assay did not require any instrumentation for the signal
read–out, which could be detected by the naked eyes within
minutes after the addition of ABTS and hydrogen peroxide,
respectively. In this work, the split G4– peroxidase probes
interrogated segment 7 of the IAV genome to unambiguously
differentiate between IAV subtypes. The analyte binding arms of
the probe were tailored to recognize the single nucleotide base
change in the genome of each strain, and only after
hybridization to the target was the visual output generated.
Each analyte was tested for multiple trials to confirm that
selectivity was successfully attained. This study highlights the
advantages of the sPDz probes for diagnostics of the Influenza A
virus which contribute to the simplicity of an instrumentindependent platform that represent an essential and promising
advancement for point of care systems.
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